

**PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC
by targeting EGFR and HER2 aberrations**

Qiuju Dong¹, Pengfei Yu³, Liang Ye³, Jianzhao Zhang², Hongbo Wang², Fangxia Zou²,
Jingwei Tian^{2,*} & Hiroshi Kurihara^{1,*}

¹School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University,
Shenyang, P.R. China.

²School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug
Evaluation (Yantai University), Ministry of Education, Collaborative Innovation
Center of Advanced Drug Delivery System and Biotech Drugs in Universities of
Shandong, Yantai University, Yantai, P.R. China.

³School of Pharmacy, Binzhou Medical University, Yantai, P.R. China.

Correspondence Authors: Hiroshi Kurihara (email: liyuanboHK@163.com) or
Jingwei Tian (email: Tianjinwei@luye.com)

In some cases, 2 membranes were detected at the same time, and the irrelevant membrane in the pictures have been mosaicated in this file. The full-length blots used in the article have not been modified.

Figure 2(c): HCC827 CDK2

From left to right: Control, PCC 0.001, PCC 0.01, PCC 0.1, Erl 0.1, Osi 0.01 (μM)




Figure 2(c): HCC827 CDK4

From left to right: Control, PCC 0.001, PCC 0.01, PCC 0.1, Erl 0.1, Osi 0.01 (μM)




Figure 2(c): HCC827 CDK6

From left to right: Control, PCC 0.001, PCC 0.01, PCC 0.1, Erl 0.1, Osi 0.01 (μM)




Figure 2(c): HCC827 E2F

From left to right: Control, PCC 0.001, PCC 0.01, PCC 0.1, Erl 0.1, Osi 0.01 (μM)




Figure 2(c): HCC827 β -actin

From left to right: Control, PCC 0.001, PCC 0.01, PCC 0.1, Erl 0.1, Osi 0.01 (μ M)




Figure 2(c): NCI-H1975 CDK2

From left to right: Control, PCC 0.01, PCC 0.1, PCC 1, Erl 1, Osi 0.1 (μ M)




Figure 2(c): NCI-H1975 CDK4

From left to right: Control, PCC 0.01, PCC 0.1, PCC 1, Erl 1, Osi 0.1 (μM)




Figure 2(c): NCI-H1975 CDK6

From left to right: Control, PCC 0.01, PCC 0.1, PCC 1, Erl 1, Osi 0.1 (μM)




Figure 2(c): NCI-H1975 E2F

From left to right: Control, PCC 0.01, PCC 0.1, PCC 1, Erl 1, Osi 0.1 (μM)




Figure 2(c): NCI-H1975 β -actin

From left to right: Control, PCC 0.01, PCC 0.1, PCC 1, Erl 1, Osi 0.1 (μM)



Figure 3(a): HCC827 pEGFR

From left to right: Control, PCC 0.001, PCC 0.01, PCC 0.1, Erl 0.1, Osi 0.01 (μM)




Figure 3(a): HCC827 EGFR

From left to right: Control, PCC 0.001, PCC 0.01, PCC 0.1, Erl 0.1, Osi 0.01 (μM)



Figure 3(a): HCC827 pAKT

From left to right: Control, PCC 0.001, PCC 0.01, PCC 0.1, Erl 0.1, Osi 0.01 (μM)




Figure 3(a): HCC827 AKT

From left to right: Control, PCC 0.001, PCC 0.01, PCC 0.1, Erl 0.1, Osi 0.01 (μM)




Figure 3(a): HCC827 pERK

From left to right: Control, PCC 0.001, PCC 0.01, PCC 0.1, Erl 0.1, Osi 0.01 (μM)



Figure 3(a): HCC827 ERK

From left to right: Control, PCC 0.001, PCC 0.01, PCC 0.1, Erl 0.1, Osi 0.01 (μM)




Figure 3(a): HCC827 β -actin

From left to right: Control, PCC 0.001, PCC 0.01, PCC 0.1, Erl 0.1, Osi 0.01 (μ M)




Figure 3(b): NCI-H1975 pEGFR

From left to right: Control, PCC 0.01, PCC 0.1, PCC 1, Erl 1, Osi 0.1 (μ M)




Figure 3(b): NCI-H1975 EGFR

From left to right: Control, PCC 0.01, PCC 0.1, PCC 1, Erl 1, Osi 0.1 (μM)




Figure 3(b): NCI-H1975 p-AKT

From left to right: Control, PCC 0.01, PCC 0.1, PCC 1, Erl 1, Osi 0.1 (μM)




Figure 3(b): NCI-H1975 AKT

From left to right: Control, PCC 0.01, PCC 0.1, PCC 1, Erl 1, Osi 0.1 (μM)




Figure 3(b): NCI-H1975 pERK

From left to right: Control, PCC 0.01, PCC 0.1, PCC 1, Erl 1, Osi 0.1 (μM)



Figure 3(b): NCI-H1975 ERK

From left to right: Control, PCC 0.01, PCC 0.1, PCC 1, Erl 1, Osi 0.1 (μM)



Figure 3(b): NCI-H1975 β -actin

From left to right: Control, PCC 0.01, PCC 0.1, PCC 1, Erl 1, Osi 0.1 (μM)



Figure 3(c): Calu3 p-Her2

From left to right: Control, PCC 0.1 μ M, Osi 0.1 μ M




Figure 3(c): Calu3 Her2

From left to right: Control, PCC 0.1 μ M, Osi 0.1 μ M




Figure 3(c): Calu3 β -actin

From left to right: Control, PCC 0.1 μ M, Osi 0.1 μ M




Figure 3(d): A431 p-EGFR

From left to right: Control, PCC 0.01 μ M, PCC 0.1 μ M, Osi 0.1 μ M, other sample




Figure 3(d): A431 EGFR

From left to right: Control, PCC 0.01 μ M, PCC 0.1 μ M, Osi 0.1 μ M, other sample



Figure 3(d): A431 β -actin

From left to right: Control, PCC 0.01 μ M, PCC 0.1 μ M, Osi 0.1 μ M, other sample

